Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep 25:12:159-169.
doi: 10.2147/CPAA.S261264. eCollection 2020.

Magnesium Sulfate Improves Some Risk Factors for Atherosclerosis in Patients Suffering from One or Two Coronary Artery Diseases: A Double-blind Clinical Trial Study

Ali Reza Sobhani  1 , Hossein Farshidi  2 , Fariba Azarkish  3 , Mahdiya Eslami  2 , Ebrahim Eftekhar  4 , Mansoor Keshavarz  5 , Nepton Soltani  6
Affiliations

Magnesium Sulfate Improves Some Risk Factors for Atherosclerosis in Patients Suffering from One or Two Coronary Artery Diseases: A Double-blind Clinical Trial Study

Ali Reza Sobhani et al. Clin Pharmacol. .

Abstract

Purpose: Given the beneficial effect of MgSO4 on the cardiovascular system, this study was designed to investigate the effect of MgSO4 administration on suppressing some atherosclerotic risk factors in moderate coronary artery disease patients with one or two atherosclerotic vessels.

Patients and methods: In a randomized double-blind placebo-controlled clinical trial study, 64 patients with moderate coronary artery disease (55-69% stenosis) were selected according to angiography findings. Patients were divided into four groups including patients with one or two atherosclerotic vessels treated with MgSO4 (Mg-treated-VR1, Mg-treated-VR2, respectively), placebo treated patients with one or two atherosclerotic vessels (Control-VR1, Control-VR2, respectively). The patients received either placebo or MgSO4 supplement capsule containing 300 mg MgSO4 for six months on a daily basis. ESR, Ca/Mg ratio, urine Mg level, serum Mg, fibrinogen, homocysteine, uric acid, Na, K, Ca, CRP, T3, T4, TSH, BUN, and Cr concentrations were measured at baseline and every three months.

Results: Serum T3, Ca, K, homocysteine, CRP, and Mg concentrations were significantly improved in Mg-treated groups compared to placebo groups.

Conclusion: The results of this study showed that despite the slight change in serum magnesium level, oral administration of MgSO4for six months could slightly reduce the serum levels of some inflammatory and vascular factors in moderate coronary artery disease patients.

Keywords: CRP; MgSO4; atherosclerosis; fibrinogen; homocysteine; thyroid hormones.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Study flow diagram.
Figure 2
Figure 2
Plasma Ca (A), Mg (B), Na (C), K (D), Cr (E), BUN (F) levels and urine Mg level (G) in MgSO4-treated moderate coronary artery disease patients with one atherosclerotic vessel (Mg-treated-VR1), MgSO4-treated moderate coronary artery disease patients with two atherosclerotic vessels (Mg-treated-VR2), placebo-treated moderate coronary artery disease patients with one atherosclerotic vessel (Control-VR1) and placebo-treated moderate coronary artery disease patients with two atherosclerotic vessels (Control-VR2). N=13 for one atherosclerotic vessel in each group and N=19 for two atherosclerotic vessels in each group. Data were presented as mean ±SD and data were analyzed using repeated measure and ANCOVA. *P<0.001 significant differences between three months Mg-treated-VR1 and before intervention (baseline) and six months after intervention. #P<0.001 significant differences between three months control-VR1 and before intervention (baseline) and six months after intervention. $P<0.01 significant differences between Mg-treated-VR2 and VR1 with control-VR2 and VR1 six months after intervention.
Figure 3
Figure 3
ESR (A), Ca/Mg ratio (B) and serum CRP (C), uric acid (D), fibrinogen (E) and homocysteine (F) levels in MgSO4-treated moderate coronary artery disease patients with one atherosclerotic vessel (Mg-treated-VR1), MgSO4-treated moderate coronary artery disease patients with two atherosclerotic vessels (Mg-treated-VR2), placebo treated moderate coronary artery disease patients with one atherosclerotic vessel (Control-VR1) and placebo treated moderate coronary artery disease patients with two atherosclerotic vessels (Control-VR2). N=13 for one atherosclerotic vessel in each group and N=19 for two atherosclerotic vessels in each group. Data were presented as mean ±SD and data were analyzed by using repeated measure and ANCOVA. *P<0.01 significant differences between VR1 and VR2 in each groups. #P<0.01 significant differences between three month Mg-treated-VR2 and before intervention (baseline) and/or six months after intervention. $P<0.01 significant differences between three months control-VR2 and before intervention (baseline) and six months after intervention and three months Mg-treated-VR2 group. @P<0.01 significant differences between Mg-treated-VR2 and VR1 with control-VR2 and VR1 six months after intervention.
Figure 4
Figure 4
Serum TSH (A), T3 (B), and T4 (C), levels in MgSO4-treated moderate coronary artery disease patients with one atherosclerotic vessel (Mg-treated-VR1), MgSO4-treated moderate coronary artery disease patients with two atherosclerotic vessels (Mg-treated-VR2), placebo treated moderate coronary artery disease patients with one atherosclerotic vessel (Control-VR1) and placebo treated moderate coronary artery disease patients with two atherosclerotic vessels (Control-VR2). N=13 for one atherosclerotic vessel in each group and N=19 for two atherosclerotic vessels in each group. Data were presented as mean ±SD and data were analyzed by using repeated measure and ANCOVA. *P<0.001 significant differences between VR1 and VR2 in each groups. **P<0.01 significant differences between three months Mg-treated-VR2 and before intervention (baseline) and six months after intervention. ***P<0.01 significant differences between Mg-treated-VR2 and VR1 with control-VR2 and VR1 six months after intervention.****P<0.01 significant differences between three months control-VR2 and before intervention (baseline) and six months after intervention and 3 months Mg-treated-VR2 group.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Torres N, Guevara-Cruz M, Velazquez-Villegas LA, Tovar AR. Nutrition and atherosclerosis. Arch Med Res. 2015;46(5):408–426. doi:10.1016/j.arcmed.2015.05.010 - DOI - PubMed
    1. Lim DH, Lee Y, Park GM, et al. Serum uric acid level and subclinical coronary atherosclerosis in asymptomatic individuals: an observational cohort study. Atherosclerosis. 2019;288:112–117. doi:10.1016/j.atherosclerosis.2019.07.017 - DOI - PubMed
    1. Orimo H, Ouchi Y. The role of calcium and magnesium in the development of atherosclerosis. Experimental and clinical evidence. Ann N Y Acad Sci. 1990;598:444–457. doi:10.1111/j.1749-6632.1990.tb42315.x - DOI - PubMed
    1. Brinkley TE, Kume N, Mitsuoka H, et al. Variation in the human lectin‐like oxidized low‐density lipoprotein receptor 1 (LOX‐1) gene is associated with plasma soluble LOX‐1 levels. Exp Physiol. 2008;93(9):1085–1090. doi:10.1113/expphysiol.2008.042267 - DOI - PMC - PubMed
    1. Blum JW, Froehli D, Kunz P. Effects of catecholamines on plasma free fatty acids in fed and fasted cattle. Endocrinology. 1982;110(2):452–456. doi:10.1210/endo-110-2-452 - DOI - PubMed